Project Summary for C-CDA R2.1 Supplemental Templates for Infectious Disease
Visit Project Insight to see the full project details. *
Project Details
Number | 1376 View Ballot Items List (with NIBs) |
---|---|
Name | C-CDA R2.1 Supplemental Templates for Infectious Disease |
Sponsor(s) | Structured Documents Work Group |
Co-Sponsor(s) | Orders and Observations Work Group, Pharmacy Work Group, Public Health Work Group |
Steering Division | Infrastructure |
Description | This project is intended to produce optional additions to the C-CDA Continuity of Care Document (CCD), Transfer Summary, and Discharge Summary standards, specifically additional templates that will specify infectious disease data that should be included in the documents when patients are transferred between healthcare facilities or discharged home. The goal of this project is to enable improvements in standards-based data exchanges of infectious disease data for purposes of improving health care and public health. The deliverables will be specific to the U.S. Realm. The intent of this project is to provide solutions that can be generalized and are not specific to healthcare-associated infection reporting.
The infectious disease data content to be covered by the optional additions to the CCD, Transfer Summary, and Discharge Summary are: (1) Infectious disease diagnosis details that supplement discharge diagnoses, such as whether or not the diagnosed infectious disease is healthcare-associated and whether or not the patient is an infectious disease carrier (i.e., colonized with an infectious disease pathogen) regardless of whether the patient was diagnosed with an infectious disease attributable to a specified pathogen (2) Microbiology laboratory results that identify the pathogen(s) implicated in the patient’s infectious disease diagnosis or carrier status, including results of antimicrobial resistance testing (3) Antimicrobial prophylaxis or treatment during the care episode at the healthcare facility or at the time of transfer or discharge from that facility, including the antimicrobial agent(s), indication(s), start date(s), dose(s),route(s)of administration, and intended duration. |
Project Facilitator | Dan Pollock |
Status | STU - Request Publication |
SD Approval Date | Nov 1, 2017 |
TSC Approval Date | Nov 13, 2007 |
Type | Ballot - STU to Normative |
Objectives / Deliverables | Submit for Draft for Comment Ballot - Target: 2018 May Ballot Complete Draft for Comment Reconciliation - Target: 2018 June Submit for STU Ballot - Target: 2018 Sept Ballot Complete STU Reconciliation - Target: 2019 Jan WGM STU Period - 24 months - Target: 2019 March - 2021 March Normative Ballot (Depends on C-CDA Normative time frame) - Target: TBD Project End Date (all objectives have been met) - Target: TBD |
Next Milestone Date | 2026 January WGM |
Project End Date | 2026 May WGM |
Project Intent | Supplement to a Current Standard, Implementation Guide |
Project Need | The immediate impetus for this project is a call for action by the U.S. Council of State and Territorial Epidemiologists (CSTE), specifically a CSTE Position Statement approved by the organization’s voting members in 2016 on Interfacility Communication to Prevent and Control Healthcare-Associated Infections and Antimicrobial Resistant Pathogens Across Healthcare Settings: www.cste.org/resource/resmgr/2016ps/16_ID_09.pdf The CSTE Position Statement describes gaps in interfacility communication that are widely recognized and widespread in healthcare. |
Implementers | 1) Cerner (Need to Confirm) 2) Epic (Need to Confirm) |
Security Risks | Yes |
External Drivers | |
Common Names / Keywords/ Aliases | |
Lineage | This project will create a supplement to HL7 CDA R2 Implementation Guide: Consolidated CDA Templates for Clinical Notes (US Realm) Draft Standard for Trial Use Release 2.1 |
Dependancies | |
Project Document Repository | http://wiki.hl7.org/index.php?title=SDWG_C-CDA_Infectious_Disease_Additions |
Backwards Compatibility | Yes |
External Vocabularies | Yes |
Products | V3 Documents-Clinical (e.g. CDA) |
Joint Copyright? | No |
External Pjt Collaborators | Centers for Disease Control and Prevention (CDC), CSTE |
Realm | Realm Specific - Enter "U.S." or name of HL7 Affiliate below |
HL7 Affiliate | U.S. |
Stakeholders | Clinical and Public Health Laboratories, Quality Reporting Agencies, Regulatory Agency, Payors |
Vendors | Pharmaceutical; EHR, PHR; Health Care IT; Clinical Decision Support Systems; Lab; HIS |
Providers | Clinical and Public Health Laboratories; Emergency Services; Local and State Departments of Health; Healthcare Institutions (hospitals, long term care, home care, mental health) |
Ballot Cycle Info | 2018 Oct Ballot Cycle Info: STU Ballot results: Met basic vote requirements. 9 Negatives to reconcile Document Name: HL7 CDA R2 Implementation Guide: C-CDA R2.1 Supplemental Templates for Infectious Disease, Release 1 - US Realm |
Misc Notes | 2019 June: TSC approved STU Publication Request for HL7 Implementation Guide(s) for CDA® Release 2: C-CDA R2.1 for 24 months. Supplemental Templates for Infectious Disease, Release 1, STU 1 - US Realm External vocabularies: LOINC, SNOMED CT, RxNorm, and ICD-10-CM are very likely. Others are TBD. |
U.S. Govt Interest? | No |
USRSC Approval | Received |
FMG Approval | Not Needed |
ARB Approval | Not Needed |
Start Date | Oct 19, 2017 |
* A Project Insight User ID and password is required to access Project Insight. Contact the HL7 PMO at for more information.
Visit the Projects, Ballots and Standards Metrics Excel Report to view projects that are behind 120+ days along with other ballots and standards requiring a Work Group's attention.
Visit the Projects, Ballots and Standards Metrics Excel Report to view projects that are behind 120+ days along with other ballots and standards requiring a Work Group's attention.